Rieltijm schreef op 2 juli 2013 15:16:
Insmed sell-off overdone, says UBS
UBS believes the sell-off in Insmed may be overdone but clearly there is pressure on NTM to deliver. The company expects to release full data at the NACF meeting in October. Shares are Buy rated with a $17.50 price target.
@Henk.L. als data NTM in oktober komt kan je misschien je drankje in de herfstvakantie doen ;-)
RT